- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05291091
Estudo de Fase 2 de EDG-5506 na Distrofia Muscular de Becker (CANYON)
Um estudo randomizado, duplo-cego e controlado por placebo de fase 2 para avaliar o efeito do EDG-5506 na segurança, biomarcadores, farmacocinética e medidas funcionais em adultos e adolescentes com distrofia muscular de Becker
A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 175 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The EDG-5506-201 protocol was amended to include an additional cohort thus consists of two parts.
Part 1: CANYON is a double-blind, randomized, placebo-controlled design to investigate the effect of sevasemten on the safety, pharmacokinetics, biomarkers, and functional measures. Approximately 32 adults and 18 adolescents with Becker muscular dystrophy are planned to enroll in this study. This study will have up to a 4-week Screening period, a 12-month Treatment period, followed by a 4-week follow-up period.
Approximately 32 adult participants will randomize to Cohort 1 or Cohort 2 in a 1:1 ratio then each cohort will further randomize to sevasemten or placebo in a 3:1 ratio.
Approximately 9 adolescent participants will enroll in Cohort 4 and randomize in a 2:1 ratio to sevasemten or placebo. Cohort 5 will randomize an additional 9 participants in a 2:1 ratio to either sevasemten or placebo after Cohort 4.
Part 2: GRAND CANYON or Cohort 6 is a double-blind, randomized, placebo-controlled design to investigate the safety and efficacy of sevasemten in adults with Becker muscular dystrophy after 18 months of treatment. Approximately 175 adults with Becker muscular dystrophy are planned to enroll in this study. This study will have up to a 4-week Screening period, an 18-month Treatment period, followed by a 4-week follow-up period.
Approximately 175 adult participants will be randomized in Cohort 6 in a 2:1 ratio either to sevasemten or placebo.
Enrollment for CANYON and GRAND CANYON has been completed.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Munich, Alemanha, 80336
- Klinikum der Ludwig-Maximilians-Universitaet Muenchen
-
-
-
-
-
Fitzroy, Austrália, VIC, 3065
- St Vincent's Hospital Melbourne
-
-
-
-
-
Leuven, Bélgica
- Universitaire Ziekenhuizen Leuven
-
Liège, Bélgica, 4000
- Centre Hospitalier Régional de la Citadelle
-
-
Belgium
-
Ghent, Belgium, Bélgica, 9000
- University Hospital Gent
-
-
-
-
-
Copenhagen, Dinamarca
- Rigshospitalet
-
-
-
-
-
Barcelona, Espanha, 08035
- Hospital Universitario Vall d'Hebron
-
Barcelona, Espanha, 08907
- Hospital Universitari de Bellvitge
-
Donostia / San Sebastian, Espanha, 20014
- Hospital Universitario Donostia
-
Valencia, Espanha, 46026
- Hospital Universitari i Politecnic La Fe
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72202
- Arkansas Children's Hospital
-
-
California
-
La Jolla, California, Estados Unidos, 92037
- UC San Diego
-
Los Angeles, California, Estados Unidos, 90095
- UCLA Medical Center
-
Orange, California, Estados Unidos, 92868
- UC Irvine Medical Center
-
Palo Alto, California, Estados Unidos, 94304
- Stanford Neuroscience Health Center
-
Sacramento, California, Estados Unidos, 95817
- UC Davis Medical Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- UC Denver
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32611
- University of Florida
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30329
- Rare Disease Research
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University School of Medicine
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21205
- Kennedy Krieger Institute
-
-
Massachusetts
-
Worcester, Massachusetts, Estados Unidos, 01605
- University of Massachusetts Memorial Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
-
New York
-
Rochester, New York, Estados Unidos, 14642
- University of Rochester Medical Center
-
-
North Carolina
-
Hillsborough, North Carolina, Estados Unidos, 27278
- Rare Disease Research, LLC NC
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- University of Cincinnati Gardner Neuroscience Institute
-
Columbus, Ohio, Estados Unidos, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- University of Pittsburgh
-
-
Texas
-
Austin, Texas, Estados Unidos, 78759
- National Neuromuscular Research Institute
-
Denton, Texas, Estados Unidos, 76208
- Neurology Rare Disease Center
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23298
- Virginia Commonwealth University Health
-
-
-
-
-
Marseille, França, 13005
- Centre de Reference des Maladies Neuromusculaires et de la SLA - AP-HM Hopital de La Timone
-
Nantes, França, 44093
- CHU de Nantes
-
Nice, França, 06001
- CHU de Nice - Hopital Pasteur 2 - Centre de reference des Maladies Neuromusculaires
-
Paris, França, 75013
- AP-HP Hopital Pitie-Salpetriere
-
-
-
-
-
Leiden, Holanda, 2333 ZA
- Leids Universitair Medisch Centrum
-
-
-
-
-
Jerusalem, Israel, 91240
- Hadassah University Hospital
-
Petah Tikva, Israel, 49202
- Schneider Children's Hospital of Israel
-
-
-
-
-
Milan, Itália, 20122
- Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano
-
Padova, Itália, 35128
- Azienda Ospedale - Università Padova
-
Rome, Itália, 00168
- Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
-
-
-
-
-
Auckland, Nova Zelândia, 1010
- Optimal Clinical Trials
-
-
-
-
-
London, Reino Unido, SW17 0QT
- St. George's University Hospitals NHS Foundation Trust
-
London, Reino Unido, NW1 2PG
- University College London Hospital
-
Newcastle, Reino Unido, NE7 7DN
- Newcastle Freeman Hospital
-
Salford, Reino Unido, M68HD
- Salford Royal Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
GRAND CANYON eligibility is listed below.
Key Inclusion Criteria:
- Adults (aged 18 to 50 years, inclusive) with a documented dystrophin mutation and phenotype consistent with Becker muscular dystrophy, and history of being ambulatory beyond 16 years of age without steroids; history of being ambulatory beyond 18 years of age with steroids.
- Able to complete the 100-meter timed test in < 200 seconds with or without use of mobility aid devices.
- Able to perform the North Star Ambulatory Assessment scale and achieve a score of 5 to 32, inclusive.
Key Exclusion Criteria:
- Medical history or clinically significant physical examination/laboratory result that, in the opinion of the investigator, would render the participant unsuitable for the study. This includes contraindications to magnetic resonance imaging such as non-compatible implanted medical devices or severe claustrophobia.
- Cardiac echocardiogram ejection fraction < 40%
- Forced vital capacity predicted <60% or using daytime ventilatory support
- Receipt of oral corticosteroids for the treatment of BMD in the previous 6 months.
- Receipt of an investigational drug within 30 days or 5 half-lives (whichever is longer) of the screening visit in the present study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Adult Cohort 1
Drug: Sevasemten Drug: Placebo |
Sevasemten is administered orally once per day Placebo is administered orally once per day |
|
Experimental: Adult Cohort 2
Drug: Sevasemten Drug: Placebo |
Sevasemten is administered orally once per day Placebo is administered orally once per day |
|
Experimental: Adult Cohort 6
Drug: Sevasemten Drug: Placebo |
Sevasemten is administered orally once per day Placebo is administered orally once per day |
|
Experimental: Adolescent Cohort 4
Drug: Sevasemten Drug: Placebo |
Placebo is administered orally once per day Sevasemten is administered orally once per day |
|
Experimental: Adolescent Cohort 5
Drug: Sevasemten Drug: Placebo |
Placebo is administered orally once per day Sevasemten is administered orally once per day |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of treatment emergent adverse events in those treated with sevasemten or placebo
Prazo: 12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
|
All participants |
12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
|
|
Severity of treatment emergent adverse events in those treated with sevasemten or placebo
Prazo: 12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
|
All participants |
12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in serum Creatine Kinase
Prazo: Averaged across Months 6, 9, 12 Months (CANYON Cohorts 1, 2)
|
Adult participants |
Averaged across Months 6, 9, 12 Months (CANYON Cohorts 1, 2)
|
|
Change from Baseline in total North Star Ambulatory Assessment score
Prazo: 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
18 months (GRAND CANYON Cohort 6)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline in total North Star Ambulatory Assessment score
Prazo: 12 Months (CANYON Cohorts 1, 2)
|
Adult participants |
12 Months (CANYON Cohorts 1, 2)
|
|
Pharmacokinetics as measured by steady state plasma concentration
Prazo: 12 Months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
|
All participants |
12 Months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in growth as assessed by height centile on World Health Organization growth charts
Prazo: 12 months (CANYON Cohorts 4, 5)
|
Adolescent participants |
12 months (CANYON Cohorts 4, 5)
|
|
Incidence of laboratory test-related treatment emergent adverse events
Prazo: 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in serum Creatine Kinase
Prazo: 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in plasma fast skeletal muscle Troponin I
Prazo: Averaged across Months 6 and 12 (CANYON Cohorts 1, 2); 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
Averaged across Months 6 and 12 (CANYON Cohorts 1, 2); 18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in serum myoglobin
Prazo: Averaged across Months 6, 9, and 12 (CANYON Cohorts 1,2); 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
Averaged across Months 6, 9, and 12 (CANYON Cohorts 1,2); 18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in total NSAD score (CANYON Cohorts 1,2)
Prazo: 12 Months (CANYON Cohorts 1, 2)
|
Adult participants |
12 Months (CANYON Cohorts 1, 2)
|
|
Change from Baseline in 4-stair climb test
Prazo: 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in the 10-meter walk/run test
Prazo: 12 Months (CANYON Cohorts 1, 2), 18 Months (GRAND CANYON Cohort 6)
|
Adult participants |
12 Months (CANYON Cohorts 1, 2), 18 Months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in 100-meter timed test
Prazo: 12 Months (CANYON Cohorts 1, 2), 18 Months (GRAND CANYON Cohort 6)
|
Adult participants |
12 Months (CANYON Cohorts 1, 2), 18 Months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in stride velocity (95th percentile)
Prazo: 18 Months (GRAND CANYON Cohort 6)
|
Adult participants |
18 Months (GRAND CANYON Cohort 6)
|
|
Month 18 change from Baseline in fat fraction of upper leg muscles as assessed by Magnetic Resonance Imaging
Prazo: 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
18 months (GRAND CANYON Cohort 6)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Joanne Donovan, MD, PhD, Edgewise Therapeutics, Inc.
- Cadeira de estudo: Roxana D. Dreghici, Edgewise Therapeutics, Inc.
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças musculoesqueléticas
- Doenças do Sistema Nervoso
- Doenças Musculares
- Doenças Neuromusculares
- Doenças Genéticas, Congênitas
- Doenças Genéticas, Ligadas ao X
- Distúrbios Musculares Atróficos
- Distrofias Musculares
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Distrofia Muscular, Duchenne
Outros números de identificação do estudo
- EDG-5506-201
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .